Featured Studies

Search our active and enrolling clinical research studies and see if you may qualify to participate.

Portico NG

symptomatic, severe native aortic stenosis
The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study. High or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure.

RADIANCE-II

Hypertension

Hypertension, or high blood pressure, affects over 1 billion people. Left untreated, high blood pressure can increase your risk of serious health problems such as heart attack, stroke, and kidney failure. Yet nearly 1 in 3 individuals with hypertension struggle to control their blood pressure despite being on medication.

If you and your physician have been unable to control your blood pressure, or are interested in an alternative to daily medications, you may be a candidate for the RADIANCE-II Clinical Study. The study is evaluating an investigative minimally-invasive, catheter-based procedure (the Paradise® Renal Denervation System) which may lower your blood pressure and reduce your need for blood pressure medications.

Low Risk “Bicuspid”

Bicuspic Aortic Valve
The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR.

Low Risk “CAP”

Aortic Valve Stenosis
The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.